Collaboration aims to uncover biomarkers for prostate cancer

04/23/2013 | GenomeWeb Daily News (free registration)

The Ontario Institute for Cancer Research has agreed to work with Johnson & Johnson unit Janssen on clinical trials that aim to develop new biomarkers for detecting hormone-resistant prostate cancer and predicting therapeutic response. The project will leverage OICR's background in molecular imaging, genomics and circulating tumor cells. As part of the project, researchers will test new imaging agents in tumor evaluation and treatment response assessment.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC